Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 16/20 | 0.42 |
| ▸ | GSK3B | P49841 | 10/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 5/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1176154 | 1.00 | DYRK1A (0.42) | DYRK1AGSK3BGSK3AWNT1FLT3 | |
| Formic Acid SCHEMBL5561679 | 0.96 | DYRK1A (0.40) | DYRK1AGSK3BGSK3AWNT1FLT3 | |
| SCHEMBL1176818 | 0.92 | GSK3B (0.48) | DYRK1AGSK3BGSK3AFLT3LRRK2 | |
| SCHEMBL5048250 | 0.92 | GSK3B (0.48) | DYRK1AGSK3BGSK3AFLT3LRRK2 | |
| Formic Acid SCHEMBL5563265 | 0.89 | GSK3B (0.46) | DYRK1AGSK3BGSK3AFLT3LRRK2 | |
| SCHEMBL1176610 | 0.86 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL5042792 | 0.86 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL1175586 | 0.85 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL5042846 | 0.85 | DYRK1A (0.56) | DYRK1AGSK3BWNT1 | |
| SCHEMBL1176497 | 0.84 | CDK2 (0.42) | DYRK1AGSK3BGSK3AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396833-B2 | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-08 | — | — | US | claimed |
| EP-1292607-B1 | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11BETA- 4E-(HYDROXYIMINOMETHYL)-PHENYL -17ALPHA-METHOXYMETHYL-17BETA-METHOXY-ESTRA-4,9-DIEN-3-ONE | BAYER SCHERING PHARMA AG (DE) | 2008-06-04 | — | — | EP | claimed |
| EP-1862469-A2 | New solid forms of mesoprogestin 11Beta-[4E-(hydroxyimino methyl)-phenyl]-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | claimed |
| EP-1697378-B1 | INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1157996-A1 | New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on | JENAPHARM GmbH (DE) | 2001-11-28 | — | — | EP | claimed |
| EP-1292607-B1 | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11BETA- 4E-(HYDROXYIMINOMETHYL)-PHENYL -17ALPHA-METHOXYMETHYL-17BETA-METHOXY-ESTRA-4,9-DIEN-3-ONE | BAYER SCHERING PHARMA AG (DE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1292607-B1 | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11BETA- 4E-(HYDROXYIMINOMETHYL)-PHENYL -17ALPHA-METHOXYMETHYL-17BETA-METHOXY-ESTRA-4,9-DIEN-3-ONE | BAYER SCHERING PHARMA AG (DE) | 2008-06-04 | — | — | EP | disclosed |
| EP-1862469-A2 | New solid forms of mesoprogestin 11Beta-[4E-(hydroxyimino methyl)-phenyl]-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1862469-A2 | New solid forms of mesoprogestin 11Beta-[4E-(hydroxyimino methyl)-phenyl]-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1292607-A2 | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11BETA- 4E-(HYDROXYIMINOMETHYL)-PHENYL]-17ALPHA-METHOXYMETHYL-17BETA-METHOXY-ESTRA-4,9-DIEN-3-ONE | Schering AG (DE) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001090137-A3 | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ONE | JENAPHARM GMBH (DE) | 2002-04-04 | — | — | WO | disclosed |
| WO-2001090137-A2 | NOVEL SOLID BODY FORMS OF MESOPROGESTIN 11β-[4E-(HYDROXYIMINOMETHYL)-PHENYL]-17α-METHOXYMETHYL-17β-METHOXY-ESTRA-4,9-DIEN-3-ONE | SCHERING AG (DE) | 2001-11-29 | — | — | WO | disclosed |
| EP-1157996-A1 | New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on | JENAPHARM GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1157996-A1 | New solid forms of mesoprogestin 11beta-(4E-(hydroxyiminomethyl)-phenyl)-17alpha-methoxymethyl-17beta-methoxy-estra-4,9-dien-3-on | JENAPHARM GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |